Evidence map›Paper›PMID 42593633›Full record

Observational studyClinical pharmacokinetics2026

Differential Oral Absorption Pharmacokinetics of Tacrolimus in Simultaneous Kidney-Pancreas Transplant Compared to Kidney Transplant Recipients.

J Kamp, A Gelinck, M Lyousoufi, S Meziyerh, H S Spijker, V A L Huurman, P J M van der Boog, A P J de Vries, D J A R Moes

Abstract readObservational StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Clinical pharmacokinetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

J Kamp *Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands. jasperk@uio.no.ORCID http://orcid.org/0000-0002-2333-1270
A Gelinck *Leiden Transplant Center, Leiden University Medical Center, Leiden, The Netherlands.
M LyousoufiLaboratory, AHZ Farmacie, The Hague, The Netherlands.
S MeziyerhLeiden Transplant Center, Leiden University Medical Center, Leiden, The Netherlands.
H S SpijkerLeiden Transplant Center, Leiden University Medical Center, Leiden, The Netherlands.
V A L HuurmanLeiden Transplant Center, Leiden University Medical Center, Leiden, The Netherlands.
P J M van der BoogLeiden Transplant Center, Leiden University Medical Center, Leiden, The Netherlands.
A P J de VriesLeiden Transplant Center, Leiden University Medical Center, Leiden, The Netherlands.
D J A R MoesDepartment of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesSimultaneous pancreas kidney transplantation (SPK) is a preferred option for type 1 diabetes (T1DM) patients with end-stage renal disease (ESRD). Most transplant centers use kidney transplant (KT) protocols target trough concentrations (C

methodsA retrospective observational study was performed to describe and compare tacrolimus population PK in SPK and KT recipients. Relevant demographic and PK data were extracted from our local transplantation database for patients transplanted between 2005 and 2020 at our hospital. Pharmacokinetic data were analyzed using nonlinear mixed effect modeling in NONMEM. Furthermore, simulations were performed to assess potential differences in AUC

resultsTacrolimus population PK in SPK and KT recipients were best described by two-compartmental models. The combined SPK and KT model showed a significantly reduced oral absorption rate for SPK recipients, compared to KT recipients (0.231 h

conclusionsWe successfully developed two separate population PK models for tacrolimus in SPK and KT recipients together with a combined SPK and KT model, showing a significantly reduced tacrolimus oral absorption rate in SPK recipients. In addition, our data suggested that SPK recipients might need higher C

Indexed as

Diabetes Mellitus, Type 1Immunosuppressive AgentsKidney TransplantationPancreas TransplantationTacrolimusAdministration, OralAdultFemaleHumansKidney Failure, ChronicMaleMiddle AgedRetrospective StudiesImmunosuppressive AgentsTacrolimus

Identifiers

PMID42593633
PMCPMC13623778

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.